Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
Sponsor: AstriVax Therapeutics
Summary
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
Official title: A Phase I, Randomized, Double-blind, Multi-centre, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Vaccine for the Prevention of Yellow Fever (AVX70120), and of AstriVax' Investigational Vaccine for the Prevention of Rabies (AVX70481), in Healthy Adults Aged 18 to 40 Years
Key Details
Gender
All
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2024-06-16
Completion Date
2026-03-31
Last Updated
2025-05-31
Healthy Volunteers
Yes
Conditions
Interventions
AVX70120 low dose level
Low dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
AVX70120 middle dose level
Middle dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
AVX70120 high dose level
High dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
AVX70481 low dose level
Low dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
AVX70481 middle dose level
Middle dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
AVX70481 high dose level
High dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
Placebo
Placebo
Locations (2)
Centre for the Evaluation of Vaccination (CEV)
Antwerp, Belgium
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent, Belgium